ABCB1单核苷酸变异对紫杉醇/白蛋白结合型紫杉醇致胃癌患者早期极重度中性粒细胞减少的影响
本研究分析203例接受紫杉醇/白蛋白结合型紫杉醇联合雷莫西尤单抗二线治疗的晚期/复发性胃癌患者,探讨ABCB1基因变异与早期极重度中性粒细胞减少(中性粒细胞<100/μL)的关联。结果显示,ABCB1 C3435T(rs1045642)TT基因型患者发生中性粒细胞<100/μL的比值比为28.1(95%CI 2.8-283.3)。
要点
- ABCB1 C3435T TT基因型与早期极重度中性粒细胞减少显著相关。
- 该关联在调整年龄、性别、基线中性粒细胞计数、血清白蛋白和AST后仍显著。
- 检测ABCB1 C3435T基因型可能有助于预测早期极重度中性粒细胞减少高风险患者。
核心结论
- ABCB1 C3435T(rs1045642)TT基因型与接受紫杉醇/白蛋白结合型紫杉醇治疗的胃癌患者发生早期极重度中性粒细胞减少显著相关。
研究设计与样本
- 回顾性分析2018年1月至2023年8月在Aichi Cancer Center Hospital治疗且DNA样本存于Cancer BioBank Aichi的患者。
- 共纳入203例接受紫杉醇/白蛋白结合型紫杉醇联合雷莫西尤单抗二线治疗的不可切除晚期/复发性胃癌患者。
- 采用Firth逻辑回归评估ABCB1 C3435T TT基因型与早期极重度中性粒细胞减少的关联,并调整年龄、性别、基线中性粒细胞计数、血清白蛋白和天冬氨酸氨基转移酶水平。
主要发现
- 203例患者中,5例(2%)发生中性粒细胞计数<100/μL。
- ABCB1 C3435T(rs1045642)TT基因型患者发生中性粒细胞计数<100/μL的比值比为28.1(95%CI 2.8-283.3)。
关键数值与推荐
- 早期极重度中性粒细胞减少定义为治疗开始后28天内中性粒细胞计数下降至<100/μL。
- 检测的ABCB1变异包括T1236C(rs1128503)、G2677T/A(rs2032582)和C3435T(rs1045642)。
临床怎么用
- 对接受紫杉醇/白蛋白结合型紫杉醇治疗的胃癌患者,可考虑检测ABCB1 C3435T(rs1045642)基因型以识别早期极重度中性粒细胞减少高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Paclitaxel and nanoparticle albumin-bound (nab)-paclitaxel can cause early, extremely severe neutropenia, occasionally leading to fatal outcomes. As paclitaxel is a substrate of P-glycoprotein, this study aimed to investigate the impact of ABCB1 single-nucleotide variants, which encode P-glycoprotein, on early, extremely severe neutropenia in patients receiving paclitaxel/nab-paclitaxel plus ramucirumab as second-line therapy for unresectable advanced/recurrent gastric cancer. METHODS: We analysed patients treated at Aichi Cancer Center Hospital from January 2018 to August 2023, with DNA samples stored in the Cancer BioBank Aichi. The impact of ABCB1 variants T1236C (rs1128503), G2677T/A (rs2032582) and C3435T (rs1045642) on early, extremely severe neutropenia was examined. Neutropenia was defined as a decline in neutrophil count to <100/μL within 28 days of therapy initiation. Firth's logistic regression evaluated the association between the ABCB1 C3435T (rs1045642) TT genotype and early, extremely severe neutropenia, adjusted for age, sex, baseline neutrophil count, and serum albumin and aspartate aminotransferase levels. RESULTS: Of the 203 eligible patients, 5 (2%) experienced neutropenia with neutrophil counts of <100/μL. The odds ratio for neutrophil counts of <100/μL was 28.1 (95% confidence interval 2.8-283.3) in patients with the ABCB1 C3435T (rs1045642) TT genotype. CONCLUSION: The ABCB1 C3435T (rs1045642) TT genotype was significantly associated with early, extremely severe neutropenia in patients receiving paclitaxel/nab-paclitaxel. Evaluating this genotype status may help predict those at increased risk for early, extremely severe neutropenia.
引用
- Maeda A, Matsuo K, Ando H, et al. Impact of ABCB1 single-nucleotide variants on early, extremely severe neutropenia induced by paclitaxel/nanoparticle albumin-bound paclitaxel in patients with gastric cancer. Br J Clin Pharmacol. 2024. PMID: 39622587. doi:10.1111/bcp.16359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。